Creutzfeldt-Jakob disease

CJD is a prion disease caused by misfolded prion proteins, with neuropathology described as deposition of misfolded prions in the brain leading to apoptotic change and spongiform alterations ^[2][3]. The literature in the supplied sources classifies CJD into sporadic, hereditary, and acquired forms, indicating heterogeneity in prion type and genetic profile ^[2]. Source-backed detail on formal ICD coding or additional etiologic subtyping is not yet available from the provided material ^[2].

The core clinical picture is a rapidly progressive neurodegenerative syndrome with psychomotor change, cognitive dysfunction, motor disorder, and behavioral abnormalities ^[2]. One review states that most patients die within a year of clinical onset, underscoring the disease’s fatal and rapidly progressive course ^[1]. Diagnostic-oriented sources note that clinical recognition is challenging and that neuropsychiatric symptoms are a key part of the presentation used in diagnostic criteria ^[3]. The provided sources do not give source-backed detail on a complete symptom timeline, specific neurologic signs, or complication patterns beyond this rapid decline ^[1][3].

The supplied review describes CJD as rare, with particular note that iatrogenic CJD is uncommon, while sporadic CJD incidence is increasing ^[1]. CJD has been discussed in the context of global incidence, prevalence, infectivity, and incubation, indicating that surveillance concerns are not limited to one setting ^[1]. Older people are specifically highlighted as an important clinical context for sporadic CJD, where the disease may resemble rapidly developing dementia ^[1]. Beyond these points, source-backed detail on regional distribution, outbreak clustering, or burden estimates is not yet available from the provided snippets ^[1].

The main transmission concern emphasized in the sources is iatrogenic transmission, with the disease able to incubate asymptomatically for decades before becoming clinically apparent ^[1]. The available material also refers to acquired forms of CJD, but it does not provide a more specific exposure route or event description in the supplied snippets ^[2]. Source-backed detail on routine person-to-person spread is not available in the provided sources ^[1][2].

The supplied sources most clearly identify older people as an important group for awareness in sporadic CJD, because presentation may resemble rapidly progressive dementia in this age range ^[1]. The literature also indicates that all genotypes have been shown to be susceptible to CJD, but source-backed detail on additional risk groups is not yet available from the provided material ^[1].

The sources support a prevention emphasis on awareness and surveillance to mitigate future transmission events, especially those related to iatrogenic risk ^[1]. Diagnostic guidance also notes that updated criteria and RT-QuIC application may improve early clinical confirmation, surveillance, and trial monitoring, which is relevant to public-health response and case recognition ^[3]. The provided material does not specify concrete exposure-control measures, instrument-processing steps, or other operational prevention practices ^[1][3].

For surveillance purposes, CJD should be read as a rare but high-consequence prion disease with prolonged silent incubation and potential iatrogenic implications ^[1]. Surveillance utility is strongest when rapidly progressive dementia or neuropsychiatric decline is investigated with attention to prion-compatible biomarkers and updated diagnostic criteria, including RT-QuIC where available ^[3]. Because sporadic CJD may present in older adults as rapidly developing dementia, case finding depends on maintaining awareness of this diagnostic possibility in routine monitoring ^[1].

1. 1 Uttley L et al. Creutzfeldt-Jakob disease: a systematic review of global incidence, prevalence, infectivity, and incubation. Lancet Infect Dis. 2020 Jan. PMID: 31876504. doi: 10.1016/S1473-3099(19)30615-2. PubMed: https://pubmed.ncbi.nlm.nih.gov/31876504/
2. 2 Noor H et al. Creutzfeldt-Jakob disease: A comprehensive review of current understanding and research. J Neurol Sci. 2024 Dec 15. PMID: 39546829. doi: 10.1016/j.jns.2024.123293. PubMed: https://pubmed.ncbi.nlm.nih.gov/39546829/
3. 3 Hermann P et al. Biomarkers and diagnostic guidelines for sporadic Creutzfeldt-Jakob disease. Lancet Neurol. 2021 Mar. PMID: 33609480. doi: 10.1016/S1474-4422(20)30477-4. PubMed: https://pubmed.ncbi.nlm.nih.gov/33609480/
4. 4 Sporadic Creutzfeldt-Jakob Disease Mimicking Variant Creutzfeldt-Jakob Disease. Archives of Neurology. 2003. doi: 10.1001/archneur.60.5.767. DOI: https://doi.org/10.1001/archneur.60.5.767
5. 5 Creutzfeldt–Jakob disease. Handbook of Clinical Neurology. 2013. doi: 10.1016/b978-0-444-52910-7.00040-4. DOI: https://doi.org/10.1016/b978-0-444-52910-7.00040-4
6. 6 Creutzfeldt–Jakob Disease. Redress Schemes for Personal Injuries. None. doi: 10.5040/9781509916641.ch-029. DOI: https://doi.org/10.5040/9781509916641.ch-029

ICD-10

ICD-11

Total cases

6K

Peak month

2023-01

Coverage

7 reporting countries · 2000-01-01 → 2017-10-01